Chippenham,
Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.
Under the partnership, Vectura will receive development fees, revenue from the provision of FOX® nebuliser devices and mid-single digit royalties from global net sales of imatinib, together with regulatory and success-related milestone payments. There is no upfront payment.
VR325, inhaled imatinib, was first developed by Vectura as part of its former speciality pharma pipeline. As the company pivoted to a strategy focused on the CDMO market, it announced it would cease further investment in this portfolio, instead providing development services to a more diverse range of biotech and pharmaceutical companies in the growing inhalation CDMO space.
Today's announcement provides an opportunity for Vectura to realise value from its historical research and investment in VR325, whilst also securing new CDMO development services revenue from the product's further development with Aerami.
1 rarediseases.org/rare-diseases/pulmonary-arterial-hypertension/
- Ends-
For more information, please contact:
About Vectura
Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has eleven key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include
For further information, please visit Vectura's website at www.vectura.com
About Aerami
Aerami Therapeutics is a biopharmaceutical company committed to developing inhaled therapies for treatment of pulmonary arterial hypertension and other severe respiratory diseases. Aerami's drug device platform consists of drug aerosol formulations and cutting-edge technology that allows for precise and fast drug delivery into the small airway of the lungs.
Forward-looking statements
This press release contains forward-looking statements, including statements about the commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward looking statements, including: commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
.
(C) 2020 M2 COMMUNICATIONS, source